Clinical Trial Search

Primary: Number of Participants With Clinical Response in Maximum Temperature (Tmax) — 8; 16 Participants

Primary: Participants Who Survived Without Requiring Invasive Mechanical Ventilation From Day 3 to Day 29, Primary Analysis — 198; 191 Participants — p=0.2874

Primary: Time to Clinical Improvement — 12; 12; 11; 12 days

Primary: C-reactive Protein (CRP) Levels at Baseline and Day 14 — 75.45; 59.8; 41.9; 38.7 mg/L

Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free

Primary: Number of Subjects Alive and Free of Respiratory Failure — 26; 20 Participants — p=0.0440

Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 19; 28…

Primary: Subjects Discharged From the Hospital Alive and Without the Need for Mechanical Ventilation. — 10; 10 Participants

Primary: Number of Participants Transferred to Intensive Care Unit (ICU) — 4 Participants

Primary: Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4) — 56.5; 49.3; 2.0; 5.6 Percentage of Participants — p=0.3600

Primary: Mechanical Ventilation or Death — 9.9; 10.0; 10.6; 12.5 percentage of patients with event — p=0.64

Primary: Efficacy - PaO2/FiO2 Ratio — 227; 209; 155; 248 mmHg (rounded)

Primary: Safety of Clazakizumab for the Treatment of Patients With COVID-19 Disease — 3; 3; 6; 8 Adverse Events — p=0.10

Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 26; 26…

Primary: Time to Improvement in Oxygenation — 4 Days

Primary: Number of Participants With Intubation or Death — 5; 1 Participants

Primary: Participants With Serious Adverse Events. — 12; 15 Participants

Primary: Area Under the Curve From Day 0-28 (AUC0-d28) of Tocilizumab) — 371; 849; 837; 1330 µg/mL*day

Primary: Percentage of Participants With Non-invasive Ventilation, Mechanical Ventilation or Death at Day 14 -- Severe COVID Population (WHO Clinical Progression Scale =5 at…

Primary: PaO2/FiO2 Change (Increase) From Pre-to-post Intervention — 16.9; 29.8 percent change

Primary: Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28 — 19; 40 Participants

Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…

Primary: Participants With a Complete Response for Cytokine Release Syndrome (CRS) — 15 Participants

Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg

Primary: Respiratory Failure-free Survival in Participants With Moderate-severe COVID-19 Who Are Treated With ATI-450 — 50; 60 percentage of total patients

Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants

Primary: Ventilator Free Survival — 58; 19; 44 Participants

Primary: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs) — 0; 0 proportion of participant

Primary: Efficacy: Proportion of Subjects Alive Not on Vasopressors, Mechanical Ventilator, or Dialysis — 27; 25 participants — p=>0.05

Primary: Proportion of Subjects Alive and Off Oxygen at 14 Days — 1; 0 Participants